AR
Andrew Reardon (CLO & Secretary) filed 9 Form 4 reports in the trailing twelve months (0 purchases, 9 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.5M of LGND (4,796 sh across 6 lots, as filed), executed Jul 1. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
9
0 buys · 9 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.4M
shares × price, as filed
Last traded
Nov 2
Filed Nov 4
Median ADV $104.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $10.5M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
9 filings
Sector per market data · by filing · past 12 months
Most traded names
LGNDRecent filings
LGNDSALE
Ligand Pharmaceuticals Incorporated
View filing →
$666K3,200 sh across 3 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $104K
1,000 sh × $104.00
Exec May 15 2025
Filed Jun 2 2025 · 5:30 PM ET †